Skip to content
Log in Join free
NephSpace cover art

Wael Hussein

NephSpace

A Medicine , Health & Fitness and Science podcast

#86 in Medicine · 🇸🇬
Good podcast? Give it some love!

About the show

NephSpace makes new kidney research easy and fun to follow. Every week, Dr. Wael Hussein, an academic nephrologist in Memphis, picks the most interesting new papers and news in nephrology, and two hosts talk them through: the story, the key numbers, why it matters, and an honest take on what the study does and doesn't prove. Weekly episodes cover that week's picks from the kidney journals, the big general journals and the specialty news. Deep Dives follow one question further: two treatments racing for the same goal, a trial worth arguing about, a case that a new paper answers. Made for nephrologists and nephrology fellows. Physician-led, AI-assisted. The hosts are AI voices. Disclosures are in every episode's notes. For education and information only, not medical advice. Please talk to your own physician or care team about your health. Full disclaimer: nephspace.com/disclaimer. Views are the creator's own and not those of his employer. Papers are summarized in our own words, with links to the originals. nephspace.com · hello@nephspace.com

Newest episodes

Weekly · Nov 9: Dialysis or Not for the Frail Older Patient, Reading Frailty at the Chair, and How to Have the Conversation

23 min

One subject this week, three papers, in the order a clinician needs them. The first randomized trial ever run on preparing a frail older patient for dialysis versus preparing them for a life without it. A bedside way to tell which patients are standing at that fork. And a framework for the conversation none of us were trained to have. Chapters 00:00 Cold open and running order 01:27 Preparing for dialysis, or not 09:59 Who counts as frail 15:04 The conversation 21:53 Close The papers Caskey FJ, et al. Preparing for responsive management versus renal dialysis in older people living with kidney failure and frailty or multimorbidity in the UK (Prepare for Kidney Care). The Lancet, online November 4, 2026. https://doi.org/10.1016/S0140-6736(26)01818-0 Ingwiller M, et al. Frailty as a Predictor of Mortality in Dialysis: A Multicenter Validation of the Clinical Frailty Scale. Kidney Medicine 2026;8(11):101510. https://doi.org/10.1016/j.xkme.2026.101510 Samyn M-C, et al. Lived Experiences of Home-Based Conservative Kidney Management in Older Adults: A Qualitative Study. AJKD 2026;88(5):692-703.e1. https://doi.org/10.1053/j.ajkd.2026.05.012 Hole B, Gelfand S. “There’s No Goal…Except That We Take Care of Them”: Meeting the Needs of People Whose Kidney Failure is Managed Conservatively. AJKD 2026;88(5):684-686. https://doi.org/10.1053/j.ajkd.2026.08.004 Schell JO, et al. Applying a Better Conversations Framework to Dialysis Decision-Making for Patients with Advanced CKD. JASN 2026;37(11):2571-2573. https://doi.org/10.1681/ASN.0000001163 Full show notes, including why “no winner” is not the same as “the two are equal”, are at nephspace.com. Disclosures. The Lancet trial had no industry funding (NIHR Health Technology Assessment programme). Among its authors, Simon Davies reports a Byonyks advisory board role and lectures for Vantive; Emma Murphy reports travel support from CSL Vifor; Caoimhe Rice is an employee of PPD Evidera; Joanna Coast developed the ICECAP measure...

Weekly · Nov 2: SGLT2 Inhibitors and Hemoglobin, Avacopan Revoked in Europe, PD Catheter Timing and Sodium on CRRT

22 min

A rising hemoglobin on an SGLT2 inhibitor: bonus, or warning sign? A meta-analysis of 85 randomized trials in JAMA puts the average rise at about 0.6 g/dL and calls its clinical significance unclear, while its editorial leans toward benefit. We read it alongside a small study of patients on SGLT2 inhibitors at altitude, where the clots clustered in those whose hemoglobin rose most, and a JASN study showing that kidney transplant recipients with polycystic kidney disease clot more, which its authors think is at least partly explained by their own higher hemoglobin. Then a first for our field: Europe revoked avacopan in August, after regulators concluded that data-integrity problems made its pivotal trial's efficacy data unreliable and that its liver-injury signal weighed against it. The FDA alleges the trial's one-year result was re-scored after unblinding; the New England Journal of Medicine retracted the paper at its academic authors' request, and the company disputes the account. Also: a registry study of when to place the peritoneal dialysis catheter, where starting within 30 days carried about three times the risk of an early complication; and a practical review of how to control the rate of sodium correction on CVVH by customizing the replacement bags. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. The peritoneal dialysis catheter segment concerns dialysis practice; that study was funded by the Canadian Institutes of Health Research with support from the International Society for Peritoneal Dialysis North American Chapter, the Ontario Renal Network, Vantive Healthcare and Medtronic, and several of its authors report ties to dialysis companies, including Vantive Healthcare and Fresenius Medical Care. Authors of the JAMA meta-analysis and of the JASN transplant study report relationships with companies that market SGLT2 inhibitors and other kidney drugs, and the authors of the JAMA editorial report consulting relatio...

Weekly · Oct 26: IgA Nephropathy's Turning Point, Access in the Very Old, SGLT2 in ADPKD and the Federal Kidney Plan

22 min

It was ASN Kidney Week, and IgA nephropathy took center stage: four phase 3 trials in the New England Journal of Medicine and an FDA accelerated approval for ravulizumab. Two drugs first approved on proteinuria, sibeprenlimab and atacicept, reported their two-year results, and kidney function barely declined. We explain why the trials arrived all at once, how the proteinuria stand-in earned its place, and where stand-ins have misled us before. Then the access center: a randomized trial in people 70 and older in which catheters needed the fewest procedures, and a bioengineered vessel for women (both conference abstracts so far). Also: empagliflozin in polycystic kidney disease, where kidneys grew faster on the drug in a small pilot; whether the PUSH stone trial tested water or coaching; how few hemodialysis guidelines say what to do with residual kidney function; a patient's view of incremental PD; and the new HHS Kidney Care National Plan, which names the ties between dialysis chains and nephrologists. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. The HHS plan segment discusses the dialysis market and the responses of dialysis companies, including Fresenius Medical Care, and the residual kidney function and incremental PD segments concern dialysis prescription, including home dialysis. Industry funding of the studies discussed: VISIONARY (Otsuka), ORIGIN 3 and PIONEER (Vera Therapeutics), I CAN (Alexion, AstraZeneca Rare Disease), RAINIER (Vertex), the iptacopan extension (Novartis), IMAgINATION (sefaxersen, Roche and Ionis) and the tissue-engineered vessel trial (Humacyte, with Humacyte authors). The empagliflozin trial in ADPKD was funded by the NIDDK and the PKD Foundation, among other non-industry sources. These disclosures were not read on air this week. Chapters 00:00 Cold open and running order01:56 IgA nephropathy: the year the endpoint changed. Sibeprenlimab (VISIONARY) and atacicept (ORIGIN 3) report two-yea...

Similar podcasts

All episodes

Weekly · Nov 9: Dialysis or Not for the Frail Older Patient, Reading Frailty at the Chair, and How to Have the Conversation

23 min

One subject this week, three papers, in the order a clinician needs them. The first randomized trial ever run on preparing a frail older patient for dialysis versus preparing them for a life without it. A bedside way to tell which patients are standing at that fork. And a framework for the conversation none of us were trained to have. Chapters 00:00 Cold open and running order 01:27 Preparing for dialysis, or not 09:59 Who counts as frail 15:04 The conversation 21:53 Close The papers Caskey FJ, et al. Preparing for responsive management versus renal dialysis in older people living with kidney failure and frailty or multimorbidity in the UK (Prepare for Kidney Care). The Lancet, online November 4, 2026. https://doi.org/10.1016/S0140-6736(26)01818-0 Ingwiller M, et al. Frailty as a Predictor of Mortality in Dialysis: A Multicenter Validation of the Clinical Frailty Scale. Kidney Medicine 2026;8(11):101510. https://doi.org/10.1016/j.xkme.2026.101510 Samyn M-C, et al. Lived Experiences of Home-Based Conservative Kidney Management in Older Adults: A Qualitative Study. AJKD 2026;88(5):692-703.e1. https://doi.org/10.1053/j.ajkd.2026.05.012 Hole B, Gelfand S. “There’s No Goal…Except That We Take Care of Them”: Meeting the Needs of People Whose Kidney Failure is Managed Conservatively. AJKD 2026;88(5):684-686. https://doi.org/10.1053/j.ajkd.2026.08.004 Schell JO, et al. Applying a Better Conversations Framework to Dialysis Decision-Making for Patients with Advanced CKD. JASN 2026;37(11):2571-2573. https://doi.org/10.1681/ASN.0000001163 Full show notes, including why “no winner” is not the same as “the two are equal”, are at nephspace.com. Disclosures. The Lancet trial had no industry funding (NIHR Health Technology Assessment programme). Among its authors, Simon Davies reports a Byonyks advisory board role and lectures for Vantive; Emma Murphy reports travel support from CSL Vifor; Caoimhe Rice is an employee of PPD Evidera; Joanna Coast developed the ICECAP measure...

Weekly · Nov 2: SGLT2 Inhibitors and Hemoglobin, Avacopan Revoked in Europe, PD Catheter Timing and Sodium on CRRT

22 min

A rising hemoglobin on an SGLT2 inhibitor: bonus, or warning sign? A meta-analysis of 85 randomized trials in JAMA puts the average rise at about 0.6 g/dL and calls its clinical significance unclear, while its editorial leans toward benefit. We read it alongside a small study of patients on SGLT2 inhibitors at altitude, where the clots clustered in those whose hemoglobin rose most, and a JASN study showing that kidney transplant recipients with polycystic kidney disease clot more, which its authors think is at least partly explained by their own higher hemoglobin. Then a first for our field: Europe revoked avacopan in August, after regulators concluded that data-integrity problems made its pivotal trial's efficacy data unreliable and that its liver-injury signal weighed against it. The FDA alleges the trial's one-year result was re-scored after unblinding; the New England Journal of Medicine retracted the paper at its academic authors' request, and the company disputes the account. Also: a registry study of when to place the peritoneal dialysis catheter, where starting within 30 days carried about three times the risk of an early complication; and a practical review of how to control the rate of sodium correction on CVVH by customizing the replacement bags. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. The peritoneal dialysis catheter segment concerns dialysis practice; that study was funded by the Canadian Institutes of Health Research with support from the International Society for Peritoneal Dialysis North American Chapter, the Ontario Renal Network, Vantive Healthcare and Medtronic, and several of its authors report ties to dialysis companies, including Vantive Healthcare and Fresenius Medical Care. Authors of the JAMA meta-analysis and of the JASN transplant study report relationships with companies that market SGLT2 inhibitors and other kidney drugs, and the authors of the JAMA editorial report consulting relatio...

Weekly · Oct 26: IgA Nephropathy's Turning Point, Access in the Very Old, SGLT2 in ADPKD and the Federal Kidney Plan

22 min

It was ASN Kidney Week, and IgA nephropathy took center stage: four phase 3 trials in the New England Journal of Medicine and an FDA accelerated approval for ravulizumab. Two drugs first approved on proteinuria, sibeprenlimab and atacicept, reported their two-year results, and kidney function barely declined. We explain why the trials arrived all at once, how the proteinuria stand-in earned its place, and where stand-ins have misled us before. Then the access center: a randomized trial in people 70 and older in which catheters needed the fewest procedures, and a bioengineered vessel for women (both conference abstracts so far). Also: empagliflozin in polycystic kidney disease, where kidneys grew faster on the drug in a small pilot; whether the PUSH stone trial tested water or coaching; how few hemodialysis guidelines say what to do with residual kidney function; a patient's view of incremental PD; and the new HHS Kidney Care National Plan, which names the ties between dialysis chains and nephrologists. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. The HHS plan segment discusses the dialysis market and the responses of dialysis companies, including Fresenius Medical Care, and the residual kidney function and incremental PD segments concern dialysis prescription, including home dialysis. Industry funding of the studies discussed: VISIONARY (Otsuka), ORIGIN 3 and PIONEER (Vera Therapeutics), I CAN (Alexion, AstraZeneca Rare Disease), RAINIER (Vertex), the iptacopan extension (Novartis), IMAgINATION (sefaxersen, Roche and Ionis) and the tissue-engineered vessel trial (Humacyte, with Humacyte authors). The empagliflozin trial in ADPKD was funded by the NIDDK and the PKD Foundation, among other non-industry sources. These disclosures were not read on air this week. Chapters 00:00 Cold open and running order01:56 IgA nephropathy: the year the endpoint changed. Sibeprenlimab (VISIONARY) and atacicept (ORIGIN 3) report two-yea...

Weekly · Oct 20: Intermittent or Continuous Dialysis in the ICU, Fluid Creep, Deprescribing and the Dialysis Bike

22 min

For years, most of us thought it didn't matter whether critically ill patients started on intermittent hemodialysis or continuous therapy. In the ICRAKI trial, starting on intermittent hemodialysis was linked to more deaths, and the trial stopped early. We explain why the size of that gap is uncertain, but its direction is harm, and why the trial couldn't show that intermittent was no worse. A JAMA study follows last week's fluids-or-pressors thread: resuscitation was only about one liter in six of ICU fluid, with maintenance and the fluid that comes in with drugs making up most of the rest. Then the dialysis unit: how hard it is to deprescribe gabapentin and other risky medications, pedaling on the dialysis bike, and what a new fistula asks of the heart. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. The exercise segment discusses a study of an exercise program implemented in Portuguese dialysis units with support from NephroCare, the clinic network of Fresenius Medical Care; two authors are affiliated with NephroCare, and outcome data came from Fresenius's clinical database. The segment also mentions hemodiafiltration, which Fresenius sells. Dr. Hussein also wrote the Healio Perspective on the deprescribing study discussed in this episode. Chapters 00:00 Cold open and running order01:27 Intermittent or continuous dialysis in the ICU: the ICRAKI trial (NEJM) set out to show intermittent hemodialysis was no worse, couldn't show that, and was stopped early after more deaths with intermittent hemodialysis as the first therapy; Dr. Paul Palevsky's editorial asks whether we're asking the right question08:00 Where ICU fluid comes from: after last week's fluids-or-pressors trial, PRoFLUID (JAMA) finds resuscitation was only about one liter in six; maintenance and the fluid that comes in with drugs and line flushes made up most of the rest10:38 Deprescribing on dialysis: the IMPROVED feasibility study (Kidney360) on stopping...

Weekly · Oct 12: Fluids or Pressors, ICU Bicarbonate and What's Holding Back PD

18 min

Three reflexes worth rethinking. In septic shock in the emergency department, stopping the fluid and starting the vasopressor early showed no difference in days alive and out of the hospital compared with the classic fluids-first approach, with about half the extra fluid. In a blinded ICU trial, sodium bicarbonate for metabolic acidosis in shock fixed the blood gas but did not significantly lower death, dialysis or lasting kidney damage. And a review of 13 interview studies asks why so few patients start peritoneal dialysis. Each with what's new, the caveats and what it means on Monday. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board; Fresenius sells peritoneal dialysis equipment. The PD segment includes our take on US payment for staff-assisted home dialysis and a bill in Congress. One author of an ASN Kidney News viewpoint discussed in the bicarbonate segment, Dr. Lenar Yessayan, reports a seat on a Fresenius Medical Care medical advisory board (the authors' own disclosure). Chapters 00:00 Cold open and running order01:12 Fluids or pressors in septic shock: in the ARISE FLUIDS trial (NEJM), stopping the fluid and starting the vasopressor early showed no difference in days alive and out of the hospital, with about half the extra fluid07:02 Bicarbonate at 2 a.m.: the blinded SODa-BIC trial (NEJM), its editorial and two ASN Kidney News viewpoints. A better blood gas, but no significant difference in death, dialysis or lasting kidney damage12:24 Why PD remains underused: an AJKD review of 13 qualitative studies finds fear, clinicians, one-session education, urgent starts and missing home support decide before the patient does17:15 Close Papers in this episode The ARISE FLUIDS Investigators and the ANZICS Clinical Trials Group and ACEM Clinical Trials Network. Vasopressors or Fluids in Early Septic Shock. N Engl J Med 2026;395:1387-1398. https://doi.org/10.1056/NEJMoa2516225The SODa-BIC Investigators and the ANZICS Clinical...

Deep Dive · Two Desks: Should AI Write the Fellow's Notes?

18 min

A 60-page referral, nine years of creatinine, and an AI summary waiting on two desks: the attending's and the first-year fellow's. A Kidney360 perspective says to hand drafting, summarizing and paperwork to AI first, because a clinician checks the draft. A CJASN perspective says that same drafting is how fellows learn judgment, and warns of "never-skilling". We look at what the evidence actually shows: an ambient-scribe trial in which the better of two tools saved about 20 seconds per note, trainees who accepted roughly three of every four wrong AI answers, and endoscopists who detected fewer adenomas on their own after AI arrived in their units. Then a Fight Night verdict. The takeaway: AI can take the paperwork off a nephrologist's desk, but the safety net is still a human who knows enough to catch its mistakes, so fellows need to build that skill before they hand anything over. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Several of the dialysis AI tools discussed come from Fresenius. He also directs quality improvement and research for nephrology fellows. Chapters 00:00 Cold open, welcome and disclosure01:22 The attending's desk: hand AI the paperwork first? The ambient-scribe trial and the dialysis AI tools07:27 The fellow's desk: never-skilling, a hallucination-spotting test, colonoscopy deskilling, and AI practice patients12:36 Who checks the checker: the ASN statement, authors' ties, and a pre-visit medication-reconciliation idea15:10 Fight Night verdict and the Monday-morning change Papers discussed Aiumtrakul N, Thongprayoon C, Cheungpasitporn W. Artificial Intelligence in Nephrology Practice: Practical Pathways to Improve Efficiency. Kidney360 2026 (ahead of print, open access). https://journals.lww.com/kidney360/fulltext/10.34067/kid.0000001424~artificial-intelligence-in-nephrology-practice-practicalFong JMN, Wang AYM. Equipping Nephrology Fellows with the Knowledge, Skills, and Attitudes for the Artific...

Weekly · Oct 5: Drugs for CKD and Dialysis, the Heart on Dialysis, and a Camera for Fistulas

24 min

A new lipid guideline makes reduced kidney function a reason for a statin; in 2024, before it arrived, most patients for whom kidney function is now the reason had no statin prescription. An editorial asks whether GLP-1 drugs belong in dialysis units before the trials are done. A review says dialysis adequacy should be measured by what it does for the heart, troponin turns out to be a moving target during a session, and an AI reads photos of fistulas. Five picks from the week of September 25, 2026, each with the background, what's new, the caveats and what it means on Monday. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Two papers in this episode have Fresenius ties: a review with coauthors affiliated with Fresenius Medical Care that rates hemodiafiltration (Fresenius makes hemodiafiltration equipment), and an AI tool from the Renal Research Institute, which authors' disclosure forms describe as a wholly owned Fresenius subsidiary. Dr. Csaba Kovesdy, author of the GLP-1 editorial, is Dr. Hussein's department chief. Chapters 00:00 Cold open and running order01:37 Statins in CKD: under the 2026 ACC/AHA guideline, an eGFR of 15 to 60 is a statin indication, but statin prescriptions were lower at more advanced CKD stages (CJASN research letter, 2024 data)06:18 GLP-1 drugs on dialysis: Dr. Kovesdy's CJASN editorial on a real-world study, its design limits, and the risks of malnutrition, muscle loss and hypoglycemia10:17 Beyond Kt/V: an NDT review weighs dialysis strategies by their cardiovascular evidence, from hemodiafiltration to potassium and sodium tailoring15:21 Troponin during dialysis: a systematic review finds troponin I can rise or fall during a single session in patients without symptoms19:21 Fistula aneurysms and AI: a photo classifier flagged 25 of 26 advanced aneurysms in a first test against in-person exams23:16 Close Papers in this episode Kim M, et al. Lipid-Lowering Therapy in Individuals with CKD. CJASN...

Trailer · Why NephSpace

2 min

I want to keep up with nephrology. But the new papers sit behind logins and scattered across sites, so I end up doomscrolling instead. NephSpace brings the week's kidney research and news together, out loud: one weekly episode on what's new, plus deep dives in between, made for the couch, the run and the drive to work. Let's transform scroll time into learning time. Knowledge, transformed: easy to reach, hard to stop. Follow on Apple Podcasts: https://podcasts.apple.com/us/podcast/nephspace/id6818364609Spotify: https://open.spotify.com/show/13ehzk9U414PYpIZK3c4yv Physician-led, AI-assisted. Dr. Wael Hussein chooses the papers and reviews and edits every script; the hosts are AI voices (ElevenLabs). Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board; each episode's notes carry its own disclosures. For education and information only, not medical advice. Please talk to your own physician or care team about your health. Full disclaimer: nephspace.com/disclaimer. Views are the creator's own and not those of his employer. nephspace.com · hello@nephspace.com

Deep Dive · Two Roads: Hemodiafiltration or Medium Cutoff Dialyzers?

20 min

Two dialysis patients, same city, same week. One gets a new machine that filters and replaces more than 20 liters every session. The other gets the same old machine with a new filter. Both are told it's the future. Hemodiafiltration has a survival trial but needs new machines. Medium cutoff dialyzers drop into today's machines but have no survival evidence against standard dialysis. A detective story with a Fight Night verdict, including who makes, sells and funds each road. The takeaway: Both roads clear more middle molecules, but only hemodiafiltration has shown that people live longer, and only in patients who can get the dose. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Fresenius makes and sells the 5008X hemodiafiltration machine discussed in this episode. The episode names the industry ties of the review authors and of everyone quoted. Chapters 00:00 Cold open and disclosure01:11 The mystery: what middle molecules are, and why clearing them might matter02:47 Road one, change the treatment: CONVINCE, its quality-of-life and cost papers, and the JASN review08:36 Road two, change the filter: Theranova, ELISIO-HX and the medium cutoff evidence11:47 The showdown: MOTheR, the head-to-head trial15:13 Follow the money: who makes, sells and funds each road16:49 Fight Night verdict and the Monday-morning change Papers discussed Blankestijn PJ, et al. Hemodiafiltration: Clinical Practice of Today and a Look into the Future. JASN 2026 (ahead of print). https://doi.org/10.1681/ASN.0000001282Healio | Nephrology, September 24, 2026. Q&A with DaVita's chief medical officer on medium cutoff dialyzers. https://www.healio.com/news/nephrology/20260924/qa-recent-fda-approval-prompts-expansion-of-medium-cutoff-dialyzersBlankestijn PJ, et al. Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure (CONVINCE). N Engl J Med 2023;389:700-709. https://doi.org/10.1056/NEJMoa2304820Rose M, et al. CONVINCE quality-of-li...

Weekly · Oct 2: The Middle-Molecule Race, a Dipstick Adherence Check, and AI for Fellows

30 min

Two ways to clear more middle molecules arrive in US dialysis units at once. A urine dipstick can show whether patients are taking their SGLT2 inhibitor. Two papers disagree about who should let AI write the notes. Nine picks from the week of September 21, 2026, each with the story, the numbers and a take. Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Fresenius sells hemodiafiltration machines, which are discussed in this episode. Chapters 00:00 Cold open and running order01:10 Hemodiafiltration: a JASN review makes the case for high-volume HDF as the global default, and how to prescribe it05:06 Medium cutoff dialyzers: Nipro's ELISIO-HX is cleared in the US and DaVita is scaling it up. What the interview shows, and what it doesn't08:13 Obinutuzumab: FDA approval for preventing relapse in frequently relapsing or steroid-dependent childhood-onset nephrotic syndrome, from age 2 into adulthood11:08 Nephrology and CKM syndrome: an AJKD perspective on shifting the specialty from organ failure to prevention13:59 Atherosclerosis in CKD: a CJASN review of mechanisms, risk prediction and the treatment menu17:54 GLP-1 receptor agonists in CKD: a case-based CJASN "How I Treat" piece21:03 The dipstick adherence check: glucosuria on routine urinalysis as a marker that patients are taking their SGLT2 inhibitor24:31 AI in practice: where AI can take paperwork off the nephrologist's desk27:44 Fellows and AI: training for the AI era without "never-skilling"30:24 Close Papers and news in this episode Blankestijn PJ, et al. Hemodiafiltration: Clinical Practice of Today and a Look into the Future. JASN 2026 (ahead of print). https://doi.org/10.1681/ASN.0000001282Healio | Nephrology, September 24, 2026. Q&A with DaVita's chief medical officer: recent FDA approval prompts expansion of medium cutoff dialyzers. https://www.healio.com/news/nephrology/20260924/qa-recent-fda-approval-prompts-expansion-of-medium-cutoff-dialyzersHealio | Nephrolo...

–

0 ratings from members

5
4
3
2
1

Rate this podcast

Log in to rate and review the shows you listen to.

No reviews yet — be the first member to rate "NephSpace".

This podcast, its content and its artwork are not owned by, affiliated with, or endorsed by Castquire.

Keep listening

Discover more podcasts like this.

Browse podcasts See the charts

Up next

  1. Nothing queued. Use + Queue on any episode to line it up.

0:00 0:00

Cookies

We set only what the site needs to sign you in and remember your theme. No advertising, no analytics. Read more.